SCYX
SCYNEXIS, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.31
−0.75%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$52.78M
MomentumView details →
1D Return
−0.75%
YTD Return
+3.36%
RSI (14)
53.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$52.78M
RSI (14)
53.8
MomentumView details →
1D Return
−0.75%
YTD Return
+3.36%
SummaryUpdated Jun 1, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company founded in 1999 and headquartered in Jersey City, New Jersey. The company went public in May 2014 and specializes in developing antifungal treatments, with a particular focus on addressing serious and life-threatening fungal infections. SCYNEXIS has successfully brought its first commercial product, BREXAFEMME, to market and continues to develop its lead compound ibrexafungerp for various fungal indications through clinical trials and strategic partnerships.
Similar companies
Latest newsMore news →